Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity DIAGNOSIS IN ONCOLOGY

Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Diagnosis & Staging, Surgery, Imaging, Pathology, CT DIAGNOSIS IN ONCOLOGY Source Type: research

Related Links:

AbstractAnti ‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely cle ar. Therefore, to identify reliable biomarkers as predictors of clinical response and resistance to anti‐PD‐1/PD‐L1 therapies have become increasingly important. Here, we report a case of a patient with bone metastatic NSCLC, who achieved a pathologic complete response after preoperative pembr olizumab treatm...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
BackgroundSeveral studies have previously demonstrated the survival benefit of both EGFR ‐TKI treatment and chemotherapy in patients with non‐small cell lung cancer (NSCLC) harboringEGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR ‐TKI therapy, focusing on the number of organs with metastasis (hereafter, metastatic organs).MethodsBetween January 2010 and December 2016, consecutive patients withEGFR‐mutated NSCLC who were started on first‐line EGFR‐TKI were reviewed. The factors influencing withholding systemic chemotherapy and the p...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Rossi G, Zullo L, Cerbone L, Coco S, Longo L, Tagliamento M, Dal Bello MG, Boccardo S, Alama A, Genova C Abstract Introduction: Poly (ADP-ribose) polymerase inhibitors (PARPi) are already part of the armamentarium of drugs available against ovarian and breast cancer. There is less data available on the efficacy of these drugs in the treatment of non-small cell lung cancer (NSCLC).Areas covered: The authors have analyzed the preclinical studies that justified the use of PARPi in NSCLC. They then evaluate the in vivo efficacy of the combination of these drugs with chemotherapy, radiotherapy, and immunotherap...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Authors: Malapelle U, Muscarella LA, Pisapia P, Rossi A Abstract Introduction: Driver molecular aberrations, such as EGFR and BRAF mutations, ALK and ROS1 rearrangements, play an important role in the oncogenesis of non-small-cell lung cancer (NSCLC). Overall, these molecular targets select about 20% of advanced nonsquamous NSCLC Caucasian patients who can be treated with the corresponding tyrosine kinase inhibitors (TKIs). Many novel driver mutations are being or have been investigated in NSCLC, with varying degrees of success and failure. These emerging molecular targets are responsible for both primary involveme...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Publication date: Available online 20 February 2020Source: The Annals of Thoracic SurgeryAuthor(s): Tingting Wang, Jiajun Deng, Yunlang She, Lei Zhang, Bin Wang, Yijiu Ren, Junqi Wu, Dong Xie, Xiwen Sun, Chang ChenAbstractBackgroundWe aimed to explore the predictive value of radiomics signature for the recurrence-free survival (RFS) in patients with resected stage I non-small-cell lung cancer (NSCLC).MethodsFrom January 2009 to December 2011, patients with resected stage I NSCLC were divided into sub-solid and pure-solid groups according to presence of ground glass opacity (GGO) in computed tomography (CT). A total of 107 ...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
A provision in the Affordable Care Act (ACA) expanded Medicaid eligibility in participating states to low-income individuals with incomes up to 138% of the federal poverty level. Medicaid expansion has been associated with earlier cancer stage at diagnosis, which we hypothesized may alter treatment patterns for patients with early stage renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and non-small lung cancer (NSCLC).
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific Session 13 Source Type: research
AbstractBackgroundPrevious studies have identified that patients withEGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT) ‐related outcomes has not been fully assessed. We studied the impact of common non‐small cell lung cancer (NSCLC) genetic alterations (EGFR,ALK andKRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.MethodsFrom 2009 –2015, 153 patients with an available genotyping status were treated with whole‐brain irradiation (WBI) before receiving systemic ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
CONCLUSIONS: Cancer diagnosis should always be considered in patients with unprovoked thrombosis and, if NSCLC is diagnosed, genetic alterations should be always sought after. A possible relation between venous thromboembolism and oncogenic drivers, particularly for ALK translocations, has been hypothesized. Similarly to ALK-positive NSCLC, ROS1 rearranged disease has been associated with an increased thromboembolic risk. Further studies are needed to better evaluate this relation and to evaluate the potential benefit of a prophylactic anticoagulating treatment in this subset of patients. PMID: 32066344 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
More News: Blueberries | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pathology | Toxicology